INSIGHTS ON CLINICAL TRIAL PARTNERING
-
![RTSM Software Isn’t One-Size-Fits-All Especially For Biotechs]( "RTSM Software Isn't One-Size-Fits-All, Especially For Small Biotechs")
RTSM Software Isn't One-Size-Fits-All, Especially For Small BiotechsSmaller biotech companies often have very different clinical trial needs than large pharmaceutical organizations, and that includes RTSM.
-
![clinical-ecoa-GettyImages-2255935744]( "The Real Reason Sites Haven't Digitized")
The Real Reason Sites Haven't DigitizedReducing site burden doesn’t require major change. Streamlining one workflow can boost efficiency, support compliance, and free staff to focus on patients.
-
![data-clinicial-GettyImages-2185301670]( "Why Your Bioanalysis Bottleneck Is Costing You More Than You Think")
Why Your Bioanalysis Bottleneck Is Costing You More Than You ThinkThis piece explains why turnaround time is a strategic variable, where speed is truly achievable, and how automation reshapes the path from sample submission to decision‑ready data.
-
![GettyImages-1181024482 payment]( "Stipends Create More Tax Burden — Here's A Better Option")
Stipends Create More Tax Burden — Here's A Better OptionExplore the tax reporting requirements, including the threshold for payments requiring a 1099 form rising from $600 to $2,000 in 2026.
-
More Than Technology: How People Make The Difference For Customers12/11/2025
Technology alone doesn’t guarantee success. Here, we explain how integrated processes, skilled teams, and collaborative partnerships complement innovation to reduce risk and improve patient outcomes.
-
ICON And Medable Drive 85% eConsent Adoption In U.S. Menopause Study4/1/2026
A site-focused strategy drove strong eConsent adoption in a complex women’s health study, showing how tailored training and hands-on support boost engagement and compliance.
-
The Rise Of Targeted Modalities In Pharmaceutical Development8/11/2025
Targeted modalities are pushing the boundaries of technology and therapeutic effectiveness. Their potential to transform patient care depends on leveraging the right expertise, technologies, and partnerships.
-
Convenient And Comprehensive Care: Best Practices For Pediatric Clinical Trials1/22/2025
Explore the role of Mobile Vision Clinics (MVCs) in enhancing pediatric clinical trials and address the critical need for safety and comfort in pediatric research.
-
Do CROs Need To Reinvent Themselves In 2025?3/21/2025
Facing economic pressures, regulatory changes, and technological advancements, CROs must redefine their value propositions and discuss the need for reinvention in 2025 to accelerate into the future.
CLINICAL TRIAL PARTNERING SOLUTIONS
-
![Human Immune System GettyImages-1201363459]( "Immune Challenge Models For Early Drug Development")
Inflammation is a primary pathogenic process in a wide range of diseases, including rheumatoid arthritis, cardiovascular disease, oncology and neuropsychiatric disorders.
-
![GettyImages-2163190867-hospital-doctor-administrator-discussion]( "Sponsors And CROs")
Our aim is to ensure the flawless and successful execution of clinical research, maximizing its impact on both patients and the commercial market.
-
![Patient Satisfaction survey-GettyImages-1356228571]( "Elevating Success: The Crucial Role Of Customer Satisfaction Programs In Companies")
By examining how satisfaction data is gathered, interpreted, and acted upon, we highlight a framework intended to strengthen relationships and enhance service quality.
-
![Eye Drop iStock-1182318206]( "Comprehensive Services For Ophthalmology Drug Development")
As a leading partner in ocular therapy, Altasciences is at the forefront of ophthalmic drug development. Our integrated CRO/CDMO solutions can support your program from lead candidate selection to market.
-
![GettyImages-1483251775-scientists-computer-analysis]( "Simplify Your Sites Operations, Patient Payments, Travel, And Logistics")
Simplify patient support in clinical trials through comprehensive expense management, travel coordination, and site services designed to reduce the burden on sites and participants.
